// Musculoskeletal System - Drugs
// Auto-generated from modularize-data.js

const drugs = [

    {
        "id": "baclofen",
        "name": "Baclofen",
        "pharmacologicClass": "central-acting-muscle-relaxants",
        "therapeuticClass": "muscle-relaxants",
        "system": "musculoskeletal-system",
        "mechanism": "Act centrally in spinal cord and brain to reduce muscle spasticity.",
        "features": "GABA-B agonist, used for spasticity.",
        "clinicalChoice": "Multiple sclerosis, spinal cord injury.",
        "indications": [
            "Multiple Sclerosis",
            "Spinal Cord Injury"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Sedation",
            "Dizziness",
            "Weakness",
            "Hepatotoxicity"
        ],
        "interactions": "CNS depressants (additive sedation), alcohol.",
        "interactionDetails": "CNS DEPRESSANTS: MECHANISM - Additive effects on GABA and other inhibitory neurotransmitter systems. CONSEQUENCE - Enhanced sedation, respiratory depression, and risk of falls, especially in elderly patients.",
        "pageType": "drug"
    },
    {
        "id": "cyclobenzaprine",
        "name": "Cyclobenzaprine",
        "pharmacologicClass": "central-acting-muscle-relaxants",
        "therapeuticClass": "muscle-relaxants",
        "system": "musculoskeletal-system",
        "mechanism": "Act centrally in spinal cord and brain to reduce muscle spasticity.",
        "features": "Tricyclic-like structure.",
        "clinicalChoice": "Acute muscle spasms.",
        "indications": [
            "Acute Muscle Spasms"
        ],
        "contraindications": [
            "MAOIs",
            "Recent MI"
        ],
        "sideEffects": [
            "Sedation",
            "Dizziness",
            "Weakness",
            "Hepatotoxicity"
        ],
        "interactions": "CNS depressants (additive sedation), alcohol.",
        "interactionDetails": "CNS DEPRESSANTS: MECHANISM - Additive effects on GABA and other inhibitory neurotransmitter systems. CONSEQUENCE - Enhanced sedation, respiratory depression, and risk of falls, especially in elderly patients.",
        "pageType": "drug"
    },
    {
        "id": "vecuronium",
        "name": "Vecuronium",
        "pharmacologicClass": "neuromuscular-blocking-agents",
        "therapeuticClass": "muscle-relaxants",
        "system": "musculoskeletal-system",
        "mechanism": "Block nicotinic receptors at neuromuscular junction.",
        "features": "Non-depolarizing, intermediate duration.",
        "clinicalChoice": "Surgical paralysis.",
        "indications": [
            "Surgical Paralysis"
        ],
        "contraindications": [
            "Hypersensitivity"
        ],
        "sideEffects": [
            "Paralysis",
            "Respiratory depression",
            "Malignant hyperthermia"
        ],
        "interactions": "Aminoglycosides potentiate blockade.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "alendronate",
        "name": "Alendronate",
        "pharmacologicClass": "bisphosphonates",
        "therapeuticClass": "bone-health",
        "system": "musculoskeletal-system",
        "mechanism": "Inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite.",
        "features": "Weekly dosing, oral.",
        "clinicalChoice": "Osteoporosis prevention and treatment.",
        "indications": [
            "Osteoporosis",
            "Paget Disease"
        ],
        "contraindications": [
            "Esophageal Abnormalities",
            "Inability to Stand"
        ],
        "sideEffects": [
            "Esophagitis",
            "Osteonecrosis of jaw",
            "Atypical fractures"
        ],
        "interactions": "Calcium, antacids reduce absorption.",
        "interactionDetails": "CALCIUM/ANTACIDS: MECHANISM - Divalent cations (Ca2+, Mg2+) chelate bisphosphonates, forming insoluble complexes. CONSEQUENCE - Markedly reduced oral bioavailability and therapeutic efficacy. Take on empty stomach.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "zoledronic-acid",
        "name": "Zoledronic acid",
        "pharmacologicClass": "bisphosphonates",
        "therapeuticClass": "bone-health",
        "system": "musculoskeletal-system",
        "mechanism": "Inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite.",
        "features": "IV infusion, annual dosing.",
        "clinicalChoice": "Severe osteoporosis, hypercalcemia.",
        "indications": [
            "Osteoporosis",
            "Hypercalcemia of Malignancy"
        ],
        "contraindications": [
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "Esophagitis",
            "Osteonecrosis of jaw",
            "Atypical fractures"
        ],
        "interactions": "Calcium, antacids reduce absorption.",
        "interactionDetails": "CALCIUM/ANTACIDS: MECHANISM - Divalent cations (Ca2+, Mg2+) chelate bisphosphonates, forming insoluble complexes. CONSEQUENCE - Markedly reduced oral bioavailability and therapeutic efficacy. Take on empty stomach.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "calcium-carbonate",
        "name": "Calcium Carbonate",
        "pharmacologicClass": "calcium-and-vitamin-d",
        "therapeuticClass": "bone-health",
        "system": "musculoskeletal-system",
        "mechanism": "Provide building blocks for bone mineralization and enhance calcium absorption.",
        "features": "Requires acid for absorption.",
        "clinicalChoice": "Osteoporosis prevention, antacid.",
        "indications": [
            "Osteoporosis Prevention",
            "Hypocalcemia"
        ],
        "contraindications": [
            "Hypercalcemia",
            "Kidney Stones"
        ],
        "sideEffects": [
            "Constipation",
            "Kidney stones",
            "Hypercalcemia"
        ],
        "interactions": "Thiazide diuretics increase calcium retention.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "calcitriol",
        "name": "Calcitriol",
        "pharmacologicClass": "calcium-and-vitamin-d",
        "therapeuticClass": "bone-health",
        "system": "musculoskeletal-system",
        "mechanism": "Provide building blocks for bone mineralization and enhance calcium absorption.",
        "features": "Active form of vitamin D.",
        "clinicalChoice": "Chronic kidney disease, hypoparathyroidism.",
        "indications": [
            "CKD",
            "Hypoparathyroidism"
        ],
        "contraindications": [
            "Hypercalcemia",
            "Vitamin D Toxicity"
        ],
        "sideEffects": [
            "Constipation",
            "Kidney stones",
            "Hypercalcemia"
        ],
        "interactions": "Thiazide diuretics increase calcium retention.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "teriparatide",
        "name": "Teriparatide",
        "pharmacologicClass": "anabolic-agents",
        "therapeuticClass": "bone-health",
        "system": "musculoskeletal-system",
        "mechanism": "Stimulate osteoblasts to increase bone formation.",
        "features": "Recombinant PTH 1-34, daily SC dosing.",
        "clinicalChoice": "Severe osteoporosis with high fracture risk or glucocorticoid-induced osteoporosis.",
        "indications": [
            "Severe Osteoporosis",
            "Glucocorticoid-Induced Osteoporosis"
        ],
        "contraindications": [
            "Paget Disease",
            "Bone Malignancy History"
        ],
        "sideEffects": [
            "Hypercalcemia",
            "Leg cramps",
            "Osteosarcoma risk (black box warning)"
        ],
        "interactions": "Avoid combination with other hypercalcemia-inducing therapies.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "denosumab",
        "name": "Denosumab",
        "pharmacologicClass": "rankl-inhibitors",
        "therapeuticClass": "bone-health",
        "system": "musculoskeletal-system",
        "mechanism": "Monoclonal antibody inhibits RANKL to block osteoclast activation.",
        "features": "Subcutaneous every 6 months.",
        "clinicalChoice": "Postmenopausal osteoporosis with high fracture risk.",
        "indications": [
            "Osteoporosis"
        ],
        "contraindications": [
            "Hypocalcemia"
        ],
        "sideEffects": [
            "Hypocalcemia",
            "Osteonecrosis of jaw",
            "Infections"
        ],
        "interactions": "Ensure adequate calcium/vitamin D to prevent hypocalcemia.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "tofacitinib",
        "name": "Tofacitinib",
        "pharmacologicClass": "jak-inhibitors",
        "therapeuticClass": "targeted-dmards",
        "system": "musculoskeletal-system",
        "mechanism": "Inhibit Janus kinases (JAK1, JAK3) to block cytokine signaling.",
        "features": "Oral JAK inhibitor, alternative to biologics.",
        "clinicalChoice": "Rheumatoid arthritis refractory to methotrexate.",
        "indications": [
            "Rheumatoid Arthritis",
            "Psoriatic Arthritis",
            "Ulcerative Colitis"
        ],
        "contraindications": [
            "Active Infection",
            "Severe Hepatic Impairment"
        ],
        "sideEffects": [
            "Infection risk",
            "Herpes zoster reactivation",
            "Thrombosis",
            "Malignancy risk"
        ],
        "interactions": "Live vaccines contraindicated, CYP3A4 interactions.",
        "interactionDetails": "THROMBOSIS: MECHANISM - JAK inhibition may affect platelet production and coagulation pathways. CONSEQUENCE - Black box warning for increased risk of blood clots, cardiovascular death. Use caution in high-risk patients.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "tizanidine",
        "name": "Tizanidine",
        "pharmacologicClass": "central-acting-muscle-relaxants",
        "therapeuticClass": "muscle-relaxants",
        "system": "musculoskeletal-system",
        "mechanism": "Alpha-2 adrenergic agonist, acts centrally to reduce muscle spasticity.",
        "features": "Alpha-2 agonist, hepatotoxicity risk.",
        "clinicalChoice": "Multiple sclerosis, spinal cord injury spasticity.",
        "indications": [
            "Multiple Sclerosis",
            "Spinal Cord Injury"
        ],
        "contraindications": [
            "Concurrent Ciprofloxacin or Fluvoxamine Use",
            "Severe Hepatic Impairment"
        ],
        "sideEffects": [
            "Sedation",
            "Hypotension",
            "Dry mouth",
            "Hepatotoxicity"
        ],
        "interactions": "CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) markedly increase levels.",
        "interactionDetails": "CYP1A2 INHIBITORS: MECHANISM - Ciprofloxacin and fluvoxamine inhibit tizanidine metabolism. CONSEQUENCE - Severe hypotension and excessive sedation. Combination contraindicated.",
        "pageType": "drug"
    },
    {
        "id": "methocarbamol",
        "name": "Methocarbamol",
        "pharmacologicClass": "central-acting-muscle-relaxants",
        "therapeuticClass": "muscle-relaxants",
        "system": "musculoskeletal-system",
        "mechanism": "Act centrally in spinal cord and brain to reduce muscle spasticity.",
        "features": "Less sedating than cyclobenzaprine.",
        "clinicalChoice": "Acute musculoskeletal pain and muscle spasms.",
        "indications": [
            "Acute Muscle Spasms",
            "Musculoskeletal Pain"
        ],
        "contraindications": [
            "Hypersensitivity",
            "Myasthenia Gravis"
        ],
        "sideEffects": [
            "Sedation",
            "Dizziness",
            "Nausea",
            "Headache"
        ],
        "interactions": "CNS depressants (additive sedation).",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "febuxostat",
        "name": "Febuxostat",
        "pharmacologicClass": "xanthine-oxidase-inhibitors",
        "therapeuticClass": "gout-medications",
        "system": "musculoskeletal-system",
        "mechanism": "Inhibit xanthine oxidase to reduce uric acid production.",
        "features": "Alternative to allopurinol, no dose adjustment in mild-moderate renal impairment.",
        "clinicalChoice": "Chronic gout in patients intolerant to allopurinol.",
        "indications": [
            "Chronic Gout",
            "Hyperuricemia"
        ],
        "contraindications": [
            "Concurrent Azathioprine or Mercaptopurine"
        ],
        "sideEffects": [
            "Gout flares initially",
            "Liver enzyme elevation",
            "Cardiovascular mortality risk"
        ],
        "interactions": "Azathioprine/mercaptopurine (severe toxicity).",
        "interactionDetails": "AZATHIOPRINE: MECHANISM - Xanthine oxidase inhibition prevents metabolism of azathioprine. CONSEQUENCE - Severe myelosuppression, potentially fatal. Contraindicated. CV RISK: Black box warning for increased cardiovascular death compared to allopurinol.",
        "highYield": true,
        "pageType": "drug"
    }

];export default drugs;
